Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.…
Cibus BioFragrance Direct-Sales Window Expands to $100 Million – Quarterly Update Report
Cibus (NASDAQ: CBUS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 118 employees.
The shares were at 1.210 USD on 20 November 2026, down 7.6% over 52 weeks. Its 52-week range is 1.016 USD to 4.191 USD: the price is 71.1% below the high and 19.1% above the low.
Its market capitalisation is 92.73M USD.
Cibus reports revenue up 30.1% year over year.
Its debt exceeds its cash by 284.54M USD, a debt-to-equity ratio of 1.51. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 16 March 2027.